2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingAlcoholismDouble-Blind MethodFemaleHumansMaleMecamylamineMiddle AgedNicotinic AntagonistsTobacco SmokingTreatment OutcomeConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differences
2012
Sex Differences in Availability of β2*-Nicotinic Acetylcholine Receptors in Recently Abstinent Tobacco Smokers
Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CM, Krishnan-Sarin S, Staley JK, Picciotto MR, O’Malley S. Sex Differences in Availability of β2*-Nicotinic Acetylcholine Receptors in Recently Abstinent Tobacco Smokers. JAMA Psychiatry 2012, 69: 418-427. PMID: 22474108, PMCID: PMC3508698, DOI: 10.1001/archgenpsychiatry.2011.1465.Peer-Reviewed Original ResearchMeSH KeywordsAdultAzetidinesBehavior, AddictiveBrainDepressionEstradiolFemaleFunctional NeuroimagingHumansIodine RadioisotopesMaleNicotinic AntagonistsProgesteronePyridinesRadioligand AssayReceptors, NicotinicSex CharacteristicsSmokingSubstance Withdrawal SyndromeTomography, Emission-Computed, Single-PhotonConceptsNAChR availabilityFemale smokersTobacco smokersNicotinic acetylcholine receptorsFemale nonsmokersProgesterone levelsAcetylcholine receptorsFemale sex steroid hormonesSex differencesSex steroid hormone levelsAbstinent tobacco smokersSex-matched nonsmokersTobacco smoking effectsMagnetic resonance imaging studyAge-matched malesEquilibrium distribution volumeEffects of nicotineSex steroid hormonesSteroid hormone levelsUnderlying neurochemical mechanismsResonance imaging studySingle photon emissionDays of abstinenceIA SPECTNicotine therapy
2009
Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: A preliminary study
McKee SA, Weinberger AH, Harrison EL, Coppola S, George TP. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: A preliminary study. Schizophrenia Research 2009, 115: 317-324. PMID: 19700263, PMCID: PMC2784178, DOI: 10.1016/j.schres.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBehavior, AddictiveDouble-Blind MethodFemaleHumansMaleMecamylamineMiddle AgedNeuropsychological TestsNicotinic AntagonistsReaction TimeSchizophreniaSelf AdministrationSmokingSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTobacco Use DisorderYoung AdultConceptsAd lib smoking behaviorNicotine levelsSmoking behaviorControl smokersSmoking topographyNicotinic receptor antagonist mecamylamineNicotinic acetylcholine receptor antagonistHealthy control smokersHigh-affinity nAChRsIntensity of smokingAd lib smokingEffects of mecamylamineNumber of cigarettesPlacebo-controlled designAcetylcholine receptor antagonistNicotine exposureAntagonist mecamylamineCompensatory smokingReceptor antagonistSmoking intensityMecamylamineSmokersSmokingSchizophreniaPreliminary study